The 'brilliant!' $15 at-home pilates app helping women ditch menopause weight gain: 'Since joining I have lost 5.7kgs'
Ladies, it's time to reclaim your mind and body for good. If you're over 40, you know your body can start to feel less like a friend and more like a foe - hello, menopause, with its hot flashes, mood swings, and weight gain.
It's easy to feel out of control as your body starts calling the shots long before you even realize that things are about to change big time. But that's where the Reverse Health Pilates app comes in.
Reverse Health Pilates
The first-ever fitness program for menopause. A platform designed for women over 40 to come together to lose weight and gain confidence using Pilates.
you can do your workout from anywhere with this unique program that is accessible via the app and online 24/7.
Whether your goal is to lose weight or gain muscle — Reverse Health has you covered.
Starting at $15 Shop
Pilates is proven to help encourage weight loss and core strengthening with low-impact routines perfect for aging
The innovative and accessible platform prioritizes women's health without judgment, bringing solutions right to you.
With their at-home pilates workouts on the app, you can take your health back into your own hands, and it only costs $15 a month.
Their program is specifically designed for women over 40 whose physical needs are unique, making other workouts such as running or weight-lifting insufficient.
The best part of all is you never have to leave the house to achieve your goals again, as every routine is accessible via the app 24/7.
As our bodies change with age, our needs do too. Reverse Health was designed with this in mind. Pilates is shown to be a low-impact strengthening fitness technique that can burn calories effectively with just a few simple moves.
Whether you are aiming to lose weight, tone muscles, or both, pilates targets it all.
Studies have shown that pilates is also a great resource in combating BMI fluctuation, which often is a major concern for women experiencing midlife weight gain.
The app comes loaded with pilates workouts, and women have reported seeing results as soon as two weeks in. (Bonus: you also unlock healthy recipes in app to help you go the extra mile!)
If you are sick and tired of empty promises, this fitness app is for you. One user said: 'I tried everything, and none of it worked until I found Reverse Health... 25 pounds later, I am back to my high school weight.'
'Feeling really proud at the steady progress in weight loss - I was very stuck at over 80kgs following menopause and feeling dejected but since joining I have lost 5.7kgs (12.5lbs) and going strong,' a second user shared.
'The wall Pilates is right up my street with the 20 minute sessions now a regular part of my morning routine.'
No matter where you are in your menopause journey or if you are a woman just looking to get fit, the Reverse Health app is going to change your life both inside and out.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
21 minutes ago
- The Sun
Worried cancer patients are flooding charity with calls asking whether fat jabs are safe to use
WORRIED cancer patients are flooding a charity with calls asking whether fat jabs are safe to use. Some of the concerns are being raised by those already having treatment such as chemo or hormone therapy. But others are fretting that using weight loss medication could increase their cancer risk. Other questions posed to Macmillan Cancer Support's helpline include asking if they were safe for someone who has had a previous thyroid cancer diagnosis, or before cancer surgery. Studies suggest the jabs might reduce the risk of some cancers but research is ongoing and they may not be safe for everyone. The rise in queries prompted the charity's Dr Owen Carter to urge caution before using the jabs. He said: 'Recently we have seen a noticeable increase in calls to Macmillan's support line and a flurry of messages on our online community about weight loss drugs. 'It's understandable that lots of people are interested in new drugs which accelerate weight loss, particularly if they want to manage their weight before or after treatment for cancer. 'While 'quick fixes' may seem attractive, we simply do not know enough about the long-term impact of these weight loss medications to recommend them if they're not prescribed by a specialist. 'Additionally, certain weight loss medications carry warnings about a potential link with thyroid cancer. 'However, we know that eating well and staying as active as possible are proven to help people feel better, increase their energy levels and strengthen their immune systems, which can help them to manage their weight and cope better with cancer treatment.' Eating well and staying active were better ways to increase energy levels and strengthen immune systems, which, in turn, would help manage weight and cope with treatment, he added. 1
Daily Mail
28 minutes ago
- Daily Mail
Top medics issue urgent warning over heart drug taken by millions - as makers AstraZeneca are accused of 'misreporting' safety data
Millions of patients at high risk of a fatal heart attack could be taking a drug that may not even be effective, top doctors have warned. Anti-clotting pill ticagrelor was approved for use on the NHS in 2011 after trials claimed it could prevent one in five deaths after a heart attack. The twice-daily pill, sold as Brilinta, is given to people with acute coronary syndrome —a sudden reduction of blood to the heart—reducing the risk of deadly clots and strokes. Since then, studies have questioned if the AstraZeneca drug is as good as its rivals, such as clopidogrel, with some even suggesting it may even increase the risk of bleeding. Now, experts have discovered 'evidence of serious misreporting' in two clinical trials, pivotal to getting the drug approved in the UK and US, 'raising doubts over its approval'. The BMJ investigation claimed the 'primary endpoint' results—the key measure to determine whether a treatment is effective—for both trials were inaccurately reported in leading cardiology journal Circulation. It also said around a quarter of the readings from machines used in the trials were not included in the data sets, the US medicine's regulator, the Food and Drug Administration (FDA) used to approve the drug. Dr Victor Serebruany, an expert in cardiovascular pharmacology at Johns Hopkins University in Maryland, who has been critical of the drug for over a decade said: 'It's been obvious for years that there is something wrong with the data. Since then, studies have questioned if the AstraZeneca drug is as good as its rivals, such as clopidogrel, with some even suggesting it may even increase the risk of bleeding 'That the FDA 's leadership could look past all these problems—on top of the many problems their own reviewers identified and are now being discovered by The BMJ—is unconscionable. 'We all need to know how and why that happened. 'If doctors had known what happened in these trials, they would never have started using ticagrelor.' In order for ticagrelor to get approved, clinical trials had to prove that it was a better drug than competitors in a phase 3 trial. After phase 3 and drug approval, the FDA and MHRA in the UK, continues monitoring it in phase 4 trials, to see if there are any additional problems with the drug. But the BMJ analysis of two phase 2 trial results found there were instances of patients who's blood 'platelet aggregation dramatically increased'. This is where platelets—a type of blood cell—stick together to form clumps which can lead to blood clots, exactly what the drug aims to prevent. It 'suggests incorrect laboratory readings', the BMJ said. Assessing the readings from platelet machines used at the two trial sites, led by cardiologist Dr Paul Gurbel, they also found more than 60 of the 282 readings were not included in the datasets submitted to the FDA. 'The platelet activity levels not entered were significantly higher than those used in the Circulation papers and FDA datasets,' they claimed. 'It is unclear whose blood was sampled, and why those measurements did not contribute to data in either trial.' A spokesperson for the Sinai Center for Thrombosis Research and Drug Development, which Dr Gurbel leads, said: 'Any allegations of any research misconduct in the two studies are baseless and erroneous.' In the UK, the drug is prescribed around 45,000 times per month on the NHS. According to medicines watchdog the National Institute for Health and Care Excellence (NICE), patients are advised to take the drug twice a day at 90mg for around a year after a heart attack. A lower dose of 60mg, may then be prescribed by doctors for up to a further three years. It may also be taken by those who have suffered a minor stroke or a transient ischaemic attack at 90mg alongside aspirin. The body naturally forms blood clots in order to patch wounds and stop bleeding. But over time, things like age, smoking and excessive weight gain can make blood clots more common. These kinds of clots also become more common after someone has a heart attack or blood vessel disorder, coronary artery disease. When someone overproduces these clots they can clog blood vessels, interrupting blood flow or weakening the walls of blood vessels, causing aneurysms and heart attacks. Circulation and AstraZeneca did not respond to a request for comment from the BMJ. MailOnline has also approached AstraZeneca for comment.
The Independent
29 minutes ago
- The Independent
Cancer patients must speak to doctors before taking weight-loss jabs
Cancer patients must speak to their doctor before taking weight-loss jabs, a charity has warned, amid a rise in people seeking help over whether they can take them. Macmillan Cancer Support said while 'quick fixes' may seem appealing, there is currently not enough evidence over how the drugs might affect anti-cancer treatments. It said more research is needed but it was already known the drugs may affect how other medicines are absorbed by the body. This may include some anti-cancer drugs, it said. Dr Owen Carter, national clinical adviser at Macmillan Cancer Support, said: 'Recently we have seen a noticeable increase in calls to Macmillan's free support line and a flurry of messages on our peer-to-peer online community about weight-loss drugs. 'We know that cancer affects everybody differently and it's understandable that lots of people are interested in new drugs which accelerate weight loss, particularly if they want to manage their weight before or after treatment for cancer. 'While 'quick fixes' may seem attractive, we simply do not know enough about the long-term impact of these weight-loss medications to recommend them if they're not prescribed by a specialist. 'Additionally, certain weight loss medications carry warnings about a potential link with thyroid cancer. 'However, we know that eating well and staying as active as possible are proven to help people feel better, increase their energy levels and strengthen their immune systems, which can help them to manage their weight and cope better with cancer treatment. 'If you have questions about cancer, including about weight-loss drugs, we urge you to speak to your GP or call the Macmillan support line. 'Trusted advisers are available 8am-8pm, seven days a week, to provide callers with information and support, or just a listening ear.' Macmillan said it has now published new information on its website about the drugs and cancer.
